Clinicians Pipeline update

Four major obesity medicine pipeline updates

Originally posted Sep 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1228 × 1536 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

Four pre-EASD updates on CagriSema, VK2735, enicepatide, and petrelintide. These are topline findings from separate clinical programs, so their results should not be compared directly.

A lot of obesity medicine pipeline news dropped this week, and EASD hasn’t even started yet.

Here’s the quick rundown on four exciting updates that stood out to me.

🔹 CagriSema

Novo Nordisk released new Phase 3 data using the lower CagriSema dose of 1.0 mg cagrilintide + 1.0 mg semaglutide.

In REIMAGINE 5, adults with type 2 diabetes lost 12.4% with CagriSema 1.0/1.0 mg versus 9.1% with tirzepatide 5 mg at 60 weeks.

Important context: this was specifically against tirzepatide 5 mg, not 10 or 15 mg.

In REDEFINE 9, that same CagriSema 1.0/1.0 mg dose produced 21.0% mean weight loss at 68 weeks in adults with overweight or obesity.

To me, the interesting part is how much efficacy Novo is seeing at a dose well below the 2.4/2.4 mg CagriSema dose studied in some of the earlier trials.

🔹 VK2735

Viking Therapeutics, Inc. reported 16.3% to 18.7% mean weight loss at 21 weeks across weekly dose groups.

A small exploratory cohort that stayed on 17.5 mg weekly reached 21.7% at 33 weeks.

The part I found most interesting was maintenance. After weekly treatment, participants maintained up to 97% of their prior weight loss with every-other-week dosing and up to 90% with monthly dosing over the next 12 weeks.

That raises the possibility that some future obesity medications may eventually use less-frequent dosing for maintenance.

🔹 Enicepatide (CT-388)

Roche reported Phase 2 data in adults with type 2 diabetes and overweight or obesity.

At 48 weeks, the 24 mg dose produced:
• 15.5% mean weight loss
• 2.65 percentage-point mean HbA1c reduction
• 90% reached HbA1c ≤6.5%
• 62% reached HbA1c <5.7%

One number that has gotten a lot of attention is the 4.13-point HbA1c reduction seen in participants who started with an HbA1c above 8.5%. That is a subgroup result, not the overall trial average, but still pretty incredible.

🔹 Petrelintide

Zealand Pharma and Roche also announced the start of the Phase 3 ZUPREME program for petrelintide, a once-weekly amylin analog.

The program will include about 7,000 participants across three Phase 3 trials.

In prior Phase 2 data, petrelintide produced up to 10.7% mean weight loss at 42 weeks, with an encouraging GI tolerability profile at the maximally effective dose.

Overall, this week’s news is a good reminder that the next phase of obesity treatment is not just about who can produce the biggest weight-loss number.

Dose optimization, maintenance strategies, glycemic control and tolerability are all becoming important.

And EASD starts next week, so there is a lot more coming!

#ObesityMedicine #Obesity #GLP1 #CagriSema #VK2735 #Enicepatide #Petrelintide #WeightManagement #ClinicalTrials

Sources & further reading

Original LinkedIn post ↗

Company announcements: Novo Nordisk: CagriSema REIMAGINE 5 and REDEFINE 9 topline results ↗

Company announcements: Viking Therapeutics: VK2735 maintenance-study topline results ↗

Company announcements: Roche: Phase II enicepatide results in adults with type 2 diabetes ↗

Company announcements: Zealand Pharma: initiation of the Phase 3 ZUPREME petrelintide program ↗

These are company topline announcements from separate programs. Trial populations, doses, durations, and comparators differ; the results are not head-to-head comparisons.

Related visuals

Four major obesity medicine pipeline updates

Pinch to zoom on touch devices. Open full image ↗